TEGRETOL CR 200 MG

Țară: Israel

Limbă: engleză

Sursă: Ministry of Health

Cumpara asta acum

Prospect Prospect (PIL)
18-07-2021

Ingredient activ:

CARBAMAZEPINE

Disponibil de la:

NOVARTIS ISRAEL LTD

Codul ATC:

N03AF01

Forma farmaceutică:

TABLETS SLOW RELEASE

Compoziție:

CARBAMAZEPINE 200 MG

Calea de administrare:

PER OS

Tip de prescriptie medicala:

Required

Produs de:

NOVARTIS FARMA S.P.A., ITALY

Grupul Terapeutică:

CARBAMAZEPINE

Zonă Terapeutică:

CARBAMAZEPINE

Indicații terapeutice:

Epilepsy, trigeminal neuralgia, diabetes insipidus, mania, prophylactic in manic-depressive illness

Data de autorizare:

2014-05-31

Prospect

                                PATIENT PACKAGE INSERT IN ACCORDANCE
WITH THE PHARMACISTS’ REGULATIONS
(PREPARATIONS) – 1986
The medicine is dispensed with a
doctor’s prescription only
TEGRETOL
®
CR 200 mg
Slow Release Tablets
Active ingredient:
Each tablet contains:
Carbamazepine 200 mg
TEGRETOL
®
CR 400 mg
Slow Release Tablets
Active ingredient:
Each tablet contains:
Carbamazepine 400 mg
TEGRETOL
®
200 mg
Tablets
Active ingredient:
Each tablet contains:
Carbamazepine 200 mg
TEGRETOL
®
SYRUP 2%
Syrup
Active ingredient:
Each 5 ml contains:
Carbamazepine 100 mg
Inactive and allergenic ingredients in the
preparation:
See section 6 ‘Further Information’ and ‘Important
information about some of the ingredients of the
medicine’ in section 2.
Read the leaflet carefully in its entirety before
using the medicine. This leaflet contains concise
information about the medicine. If you have further
questions, refer to the doctor or pharmacist.
This medicine has been prescribed for you. Do not
pass it on to others. It may harm them, even if it
seems to you that their medical condition is similar.
1. WHAT IS THE MEDICINE INTENDED FOR?
Tegretol has a number of uses:
• To treat epilepsy, a condition of recurrent seizures
(convulsions). There are many and varied types
of seizures, ranging from mild to severe.
• To treat sudden recurrent attacks of pain in the
face, known as trigeminal neuralgia.
• To treat diabetes insipidus, a condition of
increased thirst and urination.
• To treat mania, a mental condition with episodes
of hyperactivity, elation or nervousness.
• For the preventative treatment of bipolar affective
disorder (manic depression), in which there are
periods of mania alternating with periods of
depression.
Therapeutic group:
Antiepileptic, neurotropic, psychotropic.
Tegretol belongs to a class of medicines called
anticonvulsants.
These medicines apparently work by modulating the
manner in which signals are conveyed in the brain
by nerves so that attacks will not occur. Tegretol
also regulates other neural functions in the
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
TEG API FEB21 V6 REF: New Zealand September20
1.
PRODUCT NAME
TEGRETOL
®
200 mg Tablets
TEGRETOL
®
200 mg CR Tablets
TEGRETOL
®
400 mg CR Tablets
TEGRETOL
®
Syrup 2%
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE
Tablets
•
200 mg: Each tablet contains 200 mg carbamazepine
CR tablets
•
200
mg:
Each
slow-release
film-coated,
divisible
tablet
contains
200
mg
carbamazepine
•
400
mg:
Each
slow-release
film-coated,
divisible
tablet
contains
400
mg
carbamazepine
Syrup
•
5 mL: Each 5 mL of syrup contains 100 mg carbamazepine
For a full list of excipients, see section 6.1. The syrup contains
propylene glycol (refer to section
4.4, subsection _Excipients of known effect_).
3.
PHARMACEUTICAL FORM
•
Tablet containing 200mg carbamazepine. Round, white, flat tablet, 9mm
in diameter,
with bevelled edges. Imprinted CG on one side, and G/K on the scored
side. The tablet
can be divided into equal doses.
•
Controlled Release Tablet containing 200mg carbamazepine.
Beige-orange, ovaloid-
shaped, film-coated divisible tablet with slightly convex faces.
Approximate length is
12.2mm, and approximate width is 5.6mm. Both sides are scored; one
side is imprinted
C/G, and the other side H/C. The tablet can be divided into equal
doses.
•
Controlled Release Tablet containing 400mg carbamazepine.
Brown-orange, ovaloid-
shaped, film-coated divisible tablet, with slightly convex faces.
Approximately 16.7mm
in length, and approximately 6.7mm in width. Imprinted CG/CG on one
side, and
ENE/ENE on the other side; both sides are scored. The tablet can be
divided into equal
doses.
•
Syrup containing 100mg/5mL carbamazepine. A viscous white suspension
with a
caramel odour and taste. It contains sorbitol (875mg/5mL), which is
converted slowly
into glucose, making the syrup suitable for diabetics.
2
TEG API JUL23 V7 REF: New Zealand May 2023
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Epilepsy, Trigeminal neuralgia, Diabetes insipidus, Mania,
prophylactic in manic-depressive
illness.
4.2
POSOLOGY AND METHOD OF 
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect arabă 18-07-2021
Prospect Prospect ebraică 18-07-2021

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor